You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Article metrics

Article menu

Download PDFPDF

Review
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

 

Online download statistics by month:

Online download statistics by month: December 2019 to January 2026

AbstractFullPdf
Dec 2019331
Jan 202029294
Feb 202014214248
Mar 202019519562
Apr 202023823850
May 202031831840
Jun 202011911933
Jul 2020808024
Aug 2020838337
Sep 202019019053
Oct 202037537699
Nov 2020461465115
Dec 202039339398
Jan 2021371370114
Feb 202152452492
Mar 2021915915166
Apr 2021642643144
May 2021521522150
Jun 202132132175
Jul 202133633659
Aug 202139439480
Sep 202148348380
Oct 2021492492110
Nov 2021461459100
Dec 202141642998
Jan 2022384418112
Feb 202236238166
Mar 2022575628102
Apr 202245548297
May 202261464992
Jun 202239041074
Jul 202233735343
Aug 202240941755
Sep 202238640744
Oct 202236237970
Nov 202236837247
Dec 202232432557
Jan 202334134355
Feb 202333834376
Mar 2023454457107
Apr 202329429678
May 202332432870
Jun 202328328735
Jul 202332032647
Aug 202332232649
Sep 202343844051
Oct 202390891157
Nov 202349450170
Dec 202353453585
Jan 202424525082
Feb 202432833161
Mar 202448549095
Apr 202437939079
May 202440942578
Jun 202430430757
Jul 202431431652
Aug 202420721038
Sep 202424625345
Oct 202423924159
Nov 202432032562
Dec 202430332951
Jan 202535335759
Feb 202554854959
Mar 202544545463
Apr 202548148249
May 202534735053
Jun 202527027334
Jan 2026100
Total24742251654647